高新技术企业认定的专利及其价值【原创】
Introduced in 2008, "that management of high-tech enterprises" ( "new finds"), is emerging as another business to take off a "Dragon", after jumping the goal, 10 percent of companies pay less tax, corporate profits will increase 10%. Of listed companies, 10 percent increase in earnings per share of good news will bring a greater price or a premium upgrade.
On the assessment of China's high-tech enterprises, the most important thing is not their own intellectual property rights of enterprises will be "one-vote veto." Summed up in 2008 failed to pass that the causes of the key issues of most enterprises is less than the number of independent intellectual property core.
And enterprises enjoy the preferential treatment compared to an urgent requirement for patent examination and approval of the time limit is very long - from application to authorization of a utility model in general, the invention should be 3 years. Fortunately, "new found" patent-to-business flexibility, whether it is their own R & D, or transferee of others, can be. Thus, the purchase of patents has become a response. "New found" doubled after the transaction. Has become a key factor in the price, number of invention patents around 100,000 yuan in turnover, the utility model is 1 million.
In purchasing the patent, the first patent to be considered to be the framework and business counterparts in the products, not just to save money to buy a patent has nothing to do with the enterprise; if only to high-tech that it does not look at this patent has no value, and can choose One of the main framework for enterprise products and nothing of the patent, the patent if they feel valuable, do not have their own businesses, you can purchase licenses after the implementation of the patent-related enterprises, so as to achieve the best of both worlds, the three parties to benefit, namely: the successful transfer of a patent for a patent, your company that the success of high-tech and earn the approval of the patent license fees, third-party spend very little money has been a patent license.
2008年出台的《高新技术企业认定管理办法》(“高新认定”),正在成为企业腾飞的又一道“龙门”,跃过龙门之后,企业可以少交 10%的税负,企业利润就会增加10%。对上市企业来说,每股净收益增加10%的利好消息将带来股价更大的提升或溢价。
就我国高新技术企业的评审,最重要的是没有自主知识产权的企业将被“一票否决”。归纳企业在 2008 年未能通过认定的原因,大部分企业的关键问题是企业核心自主知识产权数量不足。
与企业享受优惠的迫切要求相比,专利审批的时限显得很长——从提出申请到授权,实用新型一般1年,发明要3年以上。好在“高新认定”对企业获得专利具有灵活性,无论是自己研发,还是受让别人的,皆可。于是,购买专利成了对策。“高新认定”出台后交易成倍增加。价格成了关键因素,发明专利多在10万元上下成交,实用新型则是1万元左右。
在选择购买专利时,首先要考虑专利必须要与企业的产品框架对口,不能为了省钱随便买一个与企业无关的专利;如果只是为了高新认定那就不看这个专利有没有价值了,可以选择一个主要和企业产品框架沾边的专利,如果觉得这个专利有价值,自己企业不用,可以购买以后再许可相关企业实施这个专利,从而达到两全其美、三方受益,即:专利人成功转让了专利,自己企业高新认定成功审批并且赚取了专利实施许可费,第三方花很少的钱就得到了一个专利实施许可。康生丹四代新药,化学名—三合皂甙分类引述
艾滋病免疫重建的重要意义是挽救生命的根本 点击 213
从食品植物研究开发的治疗艾滋病新药三合皂甙〔康生丹四代〕介绍 点击 567
从食品植物研究开发的治疗艾滋病新药三合皂甙 点击 245
从食品植物研究开发的治疗艾滋病新药介绍 点击 189
艾滋病的中药 点击 56
论HIV不是AIDS的病因机制 点击 78
康生丹颗粒简介 点击 67
美国营养学家推崇“抗炎饮食”同于中医之食疗 点击 123
康生丹颗粒基础研究 点击 59
艾滋病预防及国外食疗研究 点击 61
艾滋病感染者能活多久 点击 232
专家:艾滋病早治疗能多活30年以上“隐形”感染者进入晚期才被确诊 点击 99
T细胞、T细胞亚群、 调节性(或抑制性)T细胞在艾滋病康复中的研究 点击 89
你知道为什么害怕“艾滋病”这三个字么?艾滋病不同感染期症状 点击 1118
康生丹颗粒〈ksd〉对免疫抑制模型小鼠免疫功能影响实验研究-公布 点击 27
食疗与艾滋病研究-康生丹颗粒〈一〉 点击 159
艾滋病未来康复的动向分析 点击 227
艾滋病人的药膳 点击 43
首次公布康生丹提高艾滋病患者CD4的图片 点击 1379